Evercore ISI Group Maintains In-Line on Bio-Techne, Lowers Price Target to $50

Benzinga Newsdesk www.benzinga.com Neutral 54.3%

Neg 0% Neu 54.3% Pos 0%

Evercore ISI Group analyst Daniel Markowitz maintains Bio-Techne (NASDAQ:TECH) with a In-Line and lowers the price target from $54 to $50.